Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;101(1):23-31.
doi: 10.1111/cen.15018. Epub 2024 Jan 30.

The diagnostic performance of copeptin in clinical practice: A prospective study

Penelope Trimpou  1   2 , Ioannis Bounias  2 , Olof Ehn  2 , Ola Hammarsten  3 , Oskar Ragnarsson  1   2   4
Affiliations

The diagnostic performance of copeptin in clinical practice: A prospective study

Penelope Trimpou et al. Clin Endocrinol (Oxf). 2024 Jul.

Abstract

Objective: Plasma copeptin is a relatively new biomarker for evaluation of arginine vasopressin (AVP) secretion. The aim of this study was to test the diagnostic performance of copeptin in patients with polyuria-polydipsia syndrome.

Design, patients and measurements: This was a prospective study where 88 patients with polyuria-polydipsia syndrome were evaluated with a water deprivation test (WDT). Weight, urine osmolality, urine specific gravity, and plasma copeptin were collected at baseline, after 8 h, and at termination of the WDT when one of the following had been reached: (i) >3% weight reduction, (ii) urine specific gravity >1.017 or urine osmolality >600 mOsm/kg, or (iii) intolerable adverse symptoms.

Results: Of 88 patients (57 women), 21 (24%) were diagnosed with central diabetes insipidus (cDI), 5 (6%) with nephrogenic DI (nDI), and 62 (71%) with primary polydipsia (PP). Median (interquartile range) copeptin at baseline was 1.7 (1.4-2.5) pmol/L in cDI, 22 (18-65) pmol/L in nDI, and 2.7 (2-4) pmol/L in PP. After 8 h of WDT, the highest copeptin in patients with cDI was 4.0 pmol/L. In patients with PP: (i) 41 had urine osmolality <600 mOsm/kg, 7 (17%) of these had copeptin >4.0 pmol/L, (ii) 21 had urine osmolality ≥600 mOsm/kg, 14 (67%) of these had copeptin >4.0 pmol/L.

Conclusions: Copeptin >4.0 pmol/L after an overnight WDT can be used to rule out cDI and copeptin ≥21 pmol/L at baseline to diagnose nDI. The diagnostic performance of copeptin in the context of the WDT is otherwise limited in the diagnostic work-up of patients with polyuria-polydipsia syndrome.

Keywords: copeptin; diabetes insipidus; diagnostic performance; polyuria‐polydipsia syndrome; primary polydipsia.

PubMed Disclaimer

References

REFERENCES

    1. Fenske W, Quinkler M, Lorenz D, et al. Copeptin in the differential diagnosis of the polydipsia‐polyuria syndrome—revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab. 2011;96(5):1506‐1515. doi:10.1210/jc.2010-2345
    1. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112‐119. doi:10.1373/clinchem.2005.060038
    1. Keverne EB, Curley JP. Vasopressin, oxytocin and social behaviour. Curr Opin Neurobiol. 2004;14(6):777‐783. doi:10.1016/j.conb.2004.10.006
    1. Christ‐Crain M, Fenske W. Copeptin in the diagnosis of vasopressin‐dependent disorders of fluid homeostasis. Nat Rev Endocrinol. 2016;12(3):168‐176. doi:10.1038/nrendo.2015.224
    1. Fenske W, Refardt J, Chifu I, et al. A copeptin‐based approach in the diagnosis of diabetes insipidus. N Engl J Med. 2018;379(5):428‐439. doi:10.1056/NEJMoa1803760

LinkOut - more resources